Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 99 | 2024 | 21056 | 4.960 |
Why?
|
Peripheral Nervous System Diseases | 12 | 2024 | 712 | 3.590 |
Why?
|
Exercise | 49 | 2025 | 5937 | 3.540 |
Why?
|
Exercise Therapy | 23 | 2025 | 937 | 3.030 |
Why?
|
Survivors | 29 | 2022 | 2372 | 2.670 |
Why?
|
Acupuncture Therapy | 5 | 2024 | 466 | 2.390 |
Why?
|
Neoplasms | 50 | 2025 | 22340 | 2.320 |
Why?
|
Music Therapy | 4 | 2023 | 111 | 2.270 |
Why?
|
Aromatase Inhibitors | 13 | 2019 | 518 | 2.100 |
Why?
|
Yoga | 3 | 2022 | 277 | 1.750 |
Why?
|
Obesity | 33 | 2023 | 13076 | 1.710 |
Why?
|
Quality of Life | 41 | 2025 | 13462 | 1.530 |
Why?
|
Life Style | 21 | 2024 | 3926 | 1.440 |
Why?
|
Physical Fitness | 8 | 2019 | 742 | 1.320 |
Why?
|
Antineoplastic Agents | 20 | 2025 | 13648 | 1.170 |
Why?
|
Metformin | 14 | 2024 | 904 | 1.160 |
Why?
|
Weight Loss | 11 | 2022 | 2710 | 0.980 |
Why?
|
Mind-Body Therapies | 3 | 2023 | 294 | 0.970 |
Why?
|
Fatigue | 13 | 2025 | 1549 | 0.960 |
Why?
|
Health Behavior | 7 | 2024 | 2650 | 0.930 |
Why?
|
Hot Flashes | 2 | 2024 | 330 | 0.910 |
Why?
|
Body Weight | 10 | 2022 | 4622 | 0.900 |
Why?
|
Acupressure | 1 | 2023 | 13 | 0.860 |
Why?
|
Body Mass Index | 15 | 2023 | 13039 | 0.860 |
Why?
|
Receptors, Estrogen | 8 | 2024 | 2242 | 0.810 |
Why?
|
Acupuncture, Ear | 1 | 2022 | 13 | 0.790 |
Why?
|
Medical Oncology | 10 | 2022 | 2339 | 0.760 |
Why?
|
Female | 126 | 2024 | 396112 | 0.730 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 12 | 2023 | 11868 | 0.720 |
Why?
|
Humans | 177 | 2025 | 765968 | 0.690 |
Why?
|
Mobility Limitation | 1 | 2024 | 408 | 0.680 |
Why?
|
Receptor, erbB-2 | 8 | 2022 | 2593 | 0.650 |
Why?
|
Diet | 12 | 2024 | 8086 | 0.630 |
Why?
|
Anxiety | 8 | 2023 | 4671 | 0.580 |
Why?
|
Telemedicine | 4 | 2023 | 3105 | 0.580 |
Why?
|
Neoplasm Recurrence, Local | 14 | 2022 | 9373 | 0.540 |
Why?
|
Nutrition Surveys | 1 | 2024 | 1741 | 0.540 |
Why?
|
Physical Endurance | 2 | 2009 | 368 | 0.510 |
Why?
|
Paclitaxel | 5 | 2024 | 1728 | 0.510 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2024 | 1736 | 0.490 |
Why?
|
Estrogens | 2 | 2012 | 1529 | 0.490 |
Why?
|
Tertiary Prevention | 1 | 2015 | 8 | 0.490 |
Why?
|
Burnout, Professional | 1 | 2023 | 711 | 0.470 |
Why?
|
Arthralgia | 2 | 2019 | 459 | 0.470 |
Why?
|
Disabled Persons | 1 | 2024 | 1208 | 0.450 |
Why?
|
Telephone | 3 | 2014 | 627 | 0.450 |
Why?
|
Lymph Nodes | 2 | 2016 | 3454 | 0.440 |
Why?
|
Gonadal Steroid Hormones | 2 | 2021 | 705 | 0.430 |
Why?
|
Middle Aged | 65 | 2024 | 223009 | 0.410 |
Why?
|
Adult | 56 | 2024 | 223044 | 0.410 |
Why?
|
Ovarian Neoplasms | 7 | 2023 | 4900 | 0.410 |
Why?
|
Antineoplastic Agents, Hormonal | 3 | 2024 | 1534 | 0.400 |
Why?
|
Peptide Fragments | 1 | 2024 | 5125 | 0.380 |
Why?
|
Chemotherapy, Adjuvant | 9 | 2021 | 3537 | 0.380 |
Why?
|
Nitriles | 2 | 2014 | 982 | 0.350 |
Why?
|
Aged | 46 | 2024 | 171117 | 0.350 |
Why?
|
Sarcoma | 1 | 2021 | 1802 | 0.350 |
Why?
|
Triazoles | 2 | 2014 | 897 | 0.350 |
Why?
|
Resistance Training | 3 | 2024 | 196 | 0.340 |
Why?
|
Hormone Antagonists | 1 | 2010 | 108 | 0.340 |
Why?
|
Energy Metabolism | 3 | 2023 | 2892 | 0.330 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2012 | 409 | 0.330 |
Why?
|
United States | 23 | 2025 | 72903 | 0.320 |
Why?
|
Practice Guidelines as Topic | 7 | 2021 | 7425 | 0.320 |
Why?
|
Postmenopause | 4 | 2016 | 2515 | 0.320 |
Why?
|
Randomized Controlled Trials as Topic | 11 | 2024 | 10383 | 0.320 |
Why?
|
Health Promotion | 3 | 2016 | 2208 | 0.310 |
Why?
|
Diet, Reducing | 1 | 2012 | 487 | 0.310 |
Why?
|
Leptin | 4 | 2023 | 1596 | 0.310 |
Why?
|
Prognosis | 19 | 2024 | 29922 | 0.300 |
Why?
|
Stress, Psychological | 6 | 2023 | 4533 | 0.300 |
Why?
|
Survival Rate | 7 | 2016 | 12795 | 0.290 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 3 | 2010 | 920 | 0.280 |
Why?
|
Complementary Therapies | 2 | 2021 | 487 | 0.280 |
Why?
|
Women's Health | 4 | 2020 | 2084 | 0.280 |
Why?
|
Patient Education as Topic | 3 | 2020 | 2334 | 0.280 |
Why?
|
Epothilones | 2 | 2021 | 43 | 0.280 |
Why?
|
Body Composition | 5 | 2022 | 2439 | 0.270 |
Why?
|
Treatment Outcome | 25 | 2025 | 65188 | 0.270 |
Why?
|
Taxoids | 3 | 2015 | 665 | 0.270 |
Why?
|
Physicians | 2 | 2023 | 4588 | 0.260 |
Why?
|
Weight Gain | 4 | 2022 | 2355 | 0.260 |
Why?
|
Disease-Free Survival | 11 | 2023 | 6832 | 0.260 |
Why?
|
Patient Care Team | 1 | 2017 | 2517 | 0.260 |
Why?
|
Republic of Korea | 3 | 2024 | 588 | 0.260 |
Why?
|
Muscle Strength | 2 | 2024 | 637 | 0.260 |
Why?
|
Insulin | 5 | 2023 | 6599 | 0.260 |
Why?
|
Feasibility Studies | 6 | 2022 | 5302 | 0.250 |
Why?
|
Colorectal Neoplasms | 5 | 2024 | 6942 | 0.250 |
Why?
|
Attitude of Health Personnel | 1 | 2019 | 3925 | 0.240 |
Why?
|
Primary Prevention | 3 | 2019 | 1187 | 0.240 |
Why?
|
National Cancer Institute (U.S.) | 3 | 2025 | 299 | 0.240 |
Why?
|
Androgens | 1 | 2012 | 1279 | 0.230 |
Why?
|
Dietary Supplements | 1 | 2017 | 3425 | 0.230 |
Why?
|
Physician's Role | 3 | 2016 | 927 | 0.230 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2019 | 4058 | 0.230 |
Why?
|
Cause of Death | 3 | 2024 | 3708 | 0.230 |
Why?
|
Maillard Reaction | 1 | 2023 | 8 | 0.220 |
Why?
|
Societies, Medical | 4 | 2017 | 3956 | 0.220 |
Why?
|
Metabolic Diseases | 1 | 2010 | 687 | 0.220 |
Why?
|
Young Adult | 14 | 2024 | 59889 | 0.220 |
Why?
|
Organizational Objectives | 2 | 2016 | 426 | 0.220 |
Why?
|
Bone Density | 2 | 2016 | 3491 | 0.220 |
Why?
|
Pilot Projects | 6 | 2021 | 8733 | 0.210 |
Why?
|
Nurse Practitioners | 2 | 2024 | 272 | 0.210 |
Why?
|
Brain Neoplasms | 6 | 2024 | 9071 | 0.210 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2024 | 212 | 0.210 |
Why?
|
Adaptation, Psychological | 5 | 2020 | 2660 | 0.190 |
Why?
|
Vincristine | 1 | 2024 | 1039 | 0.190 |
Why?
|
Depression | 8 | 2023 | 8237 | 0.190 |
Why?
|
Hypoglycemic Agents | 7 | 2024 | 3110 | 0.190 |
Why?
|
Neoplasms, Second Primary | 1 | 2009 | 1050 | 0.190 |
Why?
|
Male | 26 | 2024 | 363698 | 0.180 |
Why?
|
China | 2 | 2024 | 2385 | 0.180 |
Why?
|
Overweight | 6 | 2022 | 2444 | 0.180 |
Why?
|
Vinblastine | 1 | 2002 | 483 | 0.180 |
Why?
|
Intention | 1 | 2023 | 346 | 0.180 |
Why?
|
Mind-Body Relations, Metaphysical | 1 | 2020 | 34 | 0.180 |
Why?
|
Integrative Medicine | 1 | 2021 | 87 | 0.170 |
Why?
|
Neoplasm Staging | 11 | 2020 | 11206 | 0.170 |
Why?
|
Risk Factors | 16 | 2020 | 74840 | 0.170 |
Why?
|
Lung Neoplasms | 2 | 2022 | 13451 | 0.170 |
Why?
|
Music | 1 | 2023 | 249 | 0.170 |
Why?
|
Follow-Up Studies | 11 | 2024 | 39193 | 0.160 |
Why?
|
Pain, Postoperative | 2 | 2020 | 1772 | 0.160 |
Why?
|
Osteoprotegerin | 1 | 2020 | 178 | 0.160 |
Why?
|
Pandemics | 4 | 2023 | 8703 | 0.160 |
Why?
|
Fractures, Bone | 1 | 2011 | 2041 | 0.160 |
Why?
|
Nausea | 1 | 2022 | 680 | 0.160 |
Why?
|
Pituitary-Adrenal System | 1 | 2022 | 547 | 0.150 |
Why?
|
Self Care | 1 | 2024 | 800 | 0.150 |
Why?
|
Vomiting | 1 | 2022 | 647 | 0.150 |
Why?
|
Fertility | 2 | 2023 | 768 | 0.150 |
Why?
|
Endocrine System | 1 | 2019 | 111 | 0.150 |
Why?
|
Interdisciplinary Communication | 2 | 2015 | 932 | 0.150 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2021 | 352 | 0.150 |
Why?
|
Biomedical Research | 4 | 2019 | 3458 | 0.150 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2022 | 697 | 0.150 |
Why?
|
Prevalence | 3 | 2024 | 15842 | 0.140 |
Why?
|
Range of Motion, Articular | 1 | 2024 | 1594 | 0.140 |
Why?
|
Clinical Trials as Topic | 7 | 2020 | 8041 | 0.140 |
Why?
|
Shoulder Joint | 1 | 2024 | 740 | 0.140 |
Why?
|
Mastectomy | 2 | 2024 | 1847 | 0.140 |
Why?
|
Saliva | 1 | 2022 | 851 | 0.140 |
Why?
|
Meditation | 1 | 2020 | 256 | 0.140 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2021 | 605 | 0.140 |
Why?
|
Mucin-1 | 1 | 2021 | 531 | 0.130 |
Why?
|
Vegetables | 1 | 2022 | 1199 | 0.130 |
Why?
|
Referral and Consultation | 2 | 2020 | 3615 | 0.130 |
Why?
|
Decision Making | 3 | 2023 | 3965 | 0.130 |
Why?
|
Disease Management | 3 | 2019 | 2535 | 0.130 |
Why?
|
Isoantibodies | 1 | 2000 | 681 | 0.130 |
Why?
|
Tamoxifen | 2 | 2011 | 963 | 0.130 |
Why?
|
Critical Pathways | 1 | 2020 | 474 | 0.130 |
Why?
|
Problem Solving | 1 | 2018 | 440 | 0.130 |
Why?
|
Premenopause | 2 | 2020 | 1037 | 0.130 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2018 | 594 | 0.130 |
Why?
|
Guidelines as Topic | 3 | 2017 | 1394 | 0.130 |
Why?
|
Aged, 80 and over | 11 | 2023 | 59489 | 0.120 |
Why?
|
Lymphedema | 2 | 2019 | 525 | 0.120 |
Why?
|
Blood Glucose | 3 | 2016 | 6424 | 0.120 |
Why?
|
Body Height | 1 | 2021 | 1562 | 0.120 |
Why?
|
Activities of Daily Living | 1 | 2024 | 2415 | 0.120 |
Why?
|
Survival Analysis | 5 | 2016 | 10070 | 0.120 |
Why?
|
Neoplasm Metastasis | 5 | 2024 | 4893 | 0.120 |
Why?
|
Adolescent | 8 | 2024 | 88835 | 0.120 |
Why?
|
Breast | 2 | 2020 | 1946 | 0.110 |
Why?
|
Tai Ji | 1 | 2017 | 289 | 0.110 |
Why?
|
Hydrocortisone | 1 | 2022 | 1827 | 0.110 |
Why?
|
Vitamin B 12 | 1 | 2017 | 532 | 0.110 |
Why?
|
Recovery of Function | 1 | 2024 | 2966 | 0.110 |
Why?
|
Mastectomy, Segmental | 2 | 2016 | 964 | 0.110 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2016 | 1776 | 0.110 |
Why?
|
Adiponectin | 3 | 2023 | 1119 | 0.110 |
Why?
|
Infection Control | 1 | 2021 | 983 | 0.110 |
Why?
|
Estrogen Replacement Therapy | 1 | 2020 | 1206 | 0.110 |
Why?
|
Health Policy | 2 | 2016 | 2698 | 0.100 |
Why?
|
Secondary Prevention | 1 | 2019 | 1472 | 0.100 |
Why?
|
Cyclophosphamide | 2 | 2015 | 2228 | 0.100 |
Why?
|
Insulin Resistance | 3 | 2023 | 3985 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2016 | 561 | 0.100 |
Why?
|
Enzyme Inhibitors | 1 | 2003 | 3715 | 0.100 |
Why?
|
Androgen Antagonists | 1 | 2021 | 1411 | 0.100 |
Why?
|
Health Education | 1 | 2019 | 1060 | 0.100 |
Why?
|
Patient Care | 1 | 2017 | 629 | 0.100 |
Why?
|
Anti-Inflammatory Agents | 1 | 2021 | 1808 | 0.100 |
Why?
|
Income | 1 | 2020 | 1874 | 0.100 |
Why?
|
Doxorubicin | 2 | 2015 | 2230 | 0.090 |
Why?
|
Nutritional Status | 3 | 2025 | 1620 | 0.090 |
Why?
|
Vaccination | 2 | 2014 | 3426 | 0.090 |
Why?
|
Colonic Neoplasms | 2 | 2013 | 2531 | 0.090 |
Why?
|
Decision Support Techniques | 1 | 2021 | 2003 | 0.090 |
Why?
|
Interleukin-6 | 2 | 2018 | 3222 | 0.090 |
Why?
|
Research Design | 3 | 2023 | 6209 | 0.090 |
Why?
|
Receptors, Progesterone | 3 | 2022 | 1153 | 0.090 |
Why?
|
Circadian Rhythm | 1 | 2022 | 2592 | 0.090 |
Why?
|
Myocardial Infarction | 1 | 2011 | 11499 | 0.090 |
Why?
|
Combined Modality Therapy | 3 | 2020 | 8529 | 0.090 |
Why?
|
Attention | 1 | 2021 | 2419 | 0.090 |
Why?
|
Erectile Dysfunction | 1 | 2014 | 437 | 0.090 |
Why?
|
Drug Administration Schedule | 2 | 2015 | 4850 | 0.090 |
Why?
|
Longitudinal Studies | 6 | 2024 | 14751 | 0.090 |
Why?
|
Benzothiazoles | 1 | 2011 | 246 | 0.090 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2014 | 363 | 0.090 |
Why?
|
Attitude to Health | 1 | 2019 | 2020 | 0.090 |
Why?
|
Immunization | 1 | 2014 | 1219 | 0.080 |
Why?
|
Prospective Studies | 8 | 2022 | 54802 | 0.080 |
Why?
|
Cardiovascular Diseases | 2 | 2019 | 15652 | 0.080 |
Why?
|
Preoperative Care | 1 | 2019 | 2267 | 0.080 |
Why?
|
Child | 4 | 2023 | 80564 | 0.080 |
Why?
|
Pain | 2 | 2022 | 5077 | 0.080 |
Why?
|
Chi-Square Distribution | 1 | 2016 | 3432 | 0.080 |
Why?
|
Lymphatic Metastasis | 2 | 2015 | 2887 | 0.080 |
Why?
|
Risk Assessment | 5 | 2019 | 24282 | 0.080 |
Why?
|
Self Report | 2 | 2021 | 3770 | 0.080 |
Why?
|
Stroke | 1 | 2011 | 9747 | 0.080 |
Why?
|
Bariatric Surgery | 1 | 2019 | 997 | 0.080 |
Why?
|
Connecticut | 2 | 2021 | 365 | 0.080 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2024 | 5337 | 0.080 |
Why?
|
Cohort Studies | 7 | 2020 | 41649 | 0.080 |
Why?
|
Receptor, Insulin | 1 | 2013 | 837 | 0.080 |
Why?
|
Reference Values | 1 | 2016 | 4908 | 0.080 |
Why?
|
Patient-Centered Care | 1 | 2018 | 1458 | 0.080 |
Why?
|
Alcohol Drinking | 2 | 2012 | 4040 | 0.070 |
Why?
|
Cardiology | 1 | 2019 | 1702 | 0.070 |
Why?
|
Catheterization, Central Venous | 1 | 2013 | 539 | 0.070 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3602 | 0.070 |
Why?
|
Forecasting | 1 | 2016 | 2936 | 0.070 |
Why?
|
Disability Evaluation | 1 | 2014 | 1820 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 2 | 2015 | 6499 | 0.070 |
Why?
|
C-Reactive Protein | 4 | 2023 | 3850 | 0.070 |
Why?
|
Motor Activity | 2 | 2014 | 2704 | 0.070 |
Why?
|
Quinazolines | 1 | 2013 | 1364 | 0.070 |
Why?
|
Early Detection of Cancer | 2 | 2019 | 3236 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2018 | 3513 | 0.070 |
Why?
|
Molecular Weight | 1 | 2009 | 2163 | 0.070 |
Why?
|
Motivation | 2 | 2018 | 2018 | 0.070 |
Why?
|
Waist-Hip Ratio | 1 | 2008 | 520 | 0.070 |
Why?
|
Ambulatory Care | 1 | 2017 | 2778 | 0.070 |
Why?
|
Proportional Hazards Models | 1 | 2021 | 12509 | 0.070 |
Why?
|
Risk Reduction Behavior | 1 | 2013 | 1123 | 0.060 |
Why?
|
Population Surveillance | 1 | 2016 | 2590 | 0.060 |
Why?
|
Cognition | 1 | 2023 | 7049 | 0.060 |
Why?
|
Communicable Diseases | 1 | 2014 | 874 | 0.060 |
Why?
|
Case-Control Studies | 3 | 2020 | 22223 | 0.060 |
Why?
|
Anthropometry | 1 | 2010 | 1338 | 0.060 |
Why?
|
Statistics, Nonparametric | 3 | 2015 | 2844 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2002 | 9249 | 0.060 |
Why?
|
Double-Blind Method | 3 | 2023 | 12437 | 0.060 |
Why?
|
Melanoma | 1 | 2023 | 5719 | 0.060 |
Why?
|
Mental Health | 1 | 2019 | 3278 | 0.060 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2008 | 521 | 0.060 |
Why?
|
Inflammation | 2 | 2023 | 10850 | 0.060 |
Why?
|
Pain Measurement | 1 | 2014 | 3561 | 0.060 |
Why?
|
Smoking | 2 | 2012 | 9081 | 0.060 |
Why?
|
Multiple Myeloma | 1 | 2022 | 5197 | 0.060 |
Why?
|
Rectal Neoplasms | 1 | 2013 | 1182 | 0.060 |
Why?
|
Time Factors | 3 | 2014 | 40065 | 0.050 |
Why?
|
Cell Proliferation | 1 | 2019 | 10429 | 0.050 |
Why?
|
Research | 1 | 2011 | 1975 | 0.050 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 2 | 2016 | 416 | 0.050 |
Why?
|
Comorbidity | 2 | 2020 | 10563 | 0.050 |
Why?
|
Diabetes Mellitus | 2 | 2013 | 5891 | 0.050 |
Why?
|
Cross-Sectional Studies | 1 | 2023 | 26318 | 0.050 |
Why?
|
Qualitative Research | 2 | 2024 | 3139 | 0.050 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2000 | 5753 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2021 | 15880 | 0.050 |
Why?
|
Platinum Compounds | 1 | 2002 | 94 | 0.050 |
Why?
|
Hypesthesia | 1 | 2021 | 106 | 0.050 |
Why?
|
Inpatients | 1 | 2013 | 2564 | 0.050 |
Why?
|
Insulin-Like Growth Factor I | 2 | 2023 | 1936 | 0.050 |
Why?
|
Social Class | 1 | 2010 | 2007 | 0.040 |
Why?
|
Macrophages | 1 | 2016 | 5772 | 0.040 |
Why?
|
Retrospective Studies | 5 | 2023 | 81514 | 0.040 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2024 | 616 | 0.040 |
Why?
|
Holistic Health | 1 | 2020 | 47 | 0.040 |
Why?
|
NAD | 1 | 2024 | 619 | 0.040 |
Why?
|
Neovascularization, Pathologic | 2 | 2024 | 2631 | 0.040 |
Why?
|
Cognition Disorders | 1 | 2014 | 3967 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2017 | 6364 | 0.040 |
Why?
|
Nerve Degeneration | 1 | 2024 | 748 | 0.040 |
Why?
|
Recurrence | 1 | 2012 | 8501 | 0.040 |
Why?
|
Heart Failure | 1 | 2024 | 11840 | 0.040 |
Why?
|
Patient Compliance | 2 | 2021 | 2692 | 0.040 |
Why?
|
Infant | 2 | 2019 | 36386 | 0.040 |
Why?
|
Risk | 1 | 2011 | 9591 | 0.040 |
Why?
|
Length of Stay | 1 | 2013 | 6485 | 0.040 |
Why?
|
Utah | 1 | 2018 | 130 | 0.040 |
Why?
|
Child, Preschool | 2 | 2019 | 42500 | 0.040 |
Why?
|
Physician Assistants | 1 | 2021 | 190 | 0.040 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2002 | 679 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2021 | 11083 | 0.040 |
Why?
|
Evidence-Based Medicine | 2 | 2021 | 3685 | 0.040 |
Why?
|
Primary Health Care | 1 | 2015 | 4736 | 0.040 |
Why?
|
Cytokines | 1 | 2013 | 7421 | 0.040 |
Why?
|
Pancreatic Neoplasms | 1 | 2016 | 5444 | 0.040 |
Why?
|
Canada | 1 | 2023 | 2119 | 0.040 |
Why?
|
User-Computer Interface | 1 | 2024 | 1405 | 0.040 |
Why?
|
Platelet Transfusion | 1 | 2000 | 296 | 0.040 |
Why?
|
Methylmalonic Acid | 1 | 2017 | 50 | 0.030 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2021 | 561 | 0.030 |
Why?
|
Mammography | 1 | 2008 | 2423 | 0.030 |
Why?
|
Placebos | 1 | 2021 | 1659 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2012 | 878 | 0.030 |
Why?
|
Ideal Body Weight | 1 | 2016 | 27 | 0.030 |
Why?
|
Axons | 1 | 2024 | 1682 | 0.030 |
Why?
|
Incidence | 2 | 2012 | 21480 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2003 | 1272 | 0.030 |
Why?
|
Insulin-Like Growth Factor Binding Protein 1 | 1 | 2016 | 125 | 0.030 |
Why?
|
Research Personnel | 1 | 2021 | 590 | 0.030 |
Why?
|
Odds Ratio | 3 | 2015 | 9649 | 0.030 |
Why?
|
Mentors | 1 | 2021 | 671 | 0.030 |
Why?
|
Behavior Therapy | 1 | 2021 | 884 | 0.030 |
Why?
|
Fasting | 1 | 2021 | 1606 | 0.030 |
Why?
|
Community Health Centers | 1 | 2019 | 469 | 0.030 |
Why?
|
Mice, Obese | 1 | 2016 | 417 | 0.030 |
Why?
|
HLA Antigens | 1 | 2000 | 1339 | 0.030 |
Why?
|
Body Size | 1 | 2017 | 459 | 0.030 |
Why?
|
Community Health Services | 1 | 2019 | 657 | 0.030 |
Why?
|
Exercise Tolerance | 1 | 2019 | 841 | 0.030 |
Why?
|
American Heart Association | 1 | 2019 | 1047 | 0.030 |
Why?
|
Switzerland | 1 | 2015 | 322 | 0.030 |
Why?
|
Administration, Oral | 1 | 2022 | 4015 | 0.030 |
Why?
|
Homocysteine | 1 | 2017 | 638 | 0.030 |
Why?
|
Sexual Behavior | 1 | 2003 | 2193 | 0.030 |
Why?
|
Estradiol | 1 | 2021 | 1947 | 0.030 |
Why?
|
Patient Care Planning | 1 | 2019 | 906 | 0.030 |
Why?
|
Occupational Therapy | 1 | 2014 | 140 | 0.030 |
Why?
|
Thinness | 1 | 2016 | 482 | 0.030 |
Why?
|
Thrombocytopenia | 1 | 2000 | 1171 | 0.020 |
Why?
|
Algorithms | 2 | 2024 | 14071 | 0.020 |
Why?
|
Lipids | 1 | 2023 | 3315 | 0.020 |
Why?
|
Exercise Test | 1 | 2019 | 2180 | 0.020 |
Why?
|
Behavior | 1 | 2014 | 535 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2019 | 953 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2013 | 12240 | 0.020 |
Why?
|
North America | 1 | 2015 | 1285 | 0.020 |
Why?
|
Standard of Care | 1 | 2015 | 567 | 0.020 |
Why?
|
Age Factors | 2 | 2020 | 18380 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 3807 | 0.020 |
Why?
|
Absorptiometry, Photon | 1 | 2016 | 1707 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2021 | 2243 | 0.020 |
Why?
|
Gastric Bypass | 1 | 2019 | 820 | 0.020 |
Why?
|
Continuity of Patient Care | 1 | 2017 | 1078 | 0.020 |
Why?
|
Piperazines | 1 | 2021 | 2549 | 0.020 |
Why?
|
Nurses | 1 | 2020 | 2505 | 0.020 |
Why?
|
Methylphenidate | 1 | 2014 | 479 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2013 | 591 | 0.020 |
Why?
|
Testosterone | 1 | 2021 | 2494 | 0.020 |
Why?
|
Catheter-Related Infections | 1 | 2013 | 279 | 0.020 |
Why?
|
Epidemiologic Research Design | 1 | 2013 | 368 | 0.020 |
Why?
|
Economics | 1 | 2010 | 141 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2013 | 791 | 0.020 |
Why?
|
Consensus | 1 | 2019 | 3202 | 0.020 |
Why?
|
Pyridines | 1 | 2021 | 2888 | 0.020 |
Why?
|
Marital Status | 1 | 2010 | 426 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2019 | 2780 | 0.020 |
Why?
|
Evaluation Studies as Topic | 1 | 2010 | 1600 | 0.020 |
Why?
|
Meta-Analysis as Topic | 1 | 2013 | 1370 | 0.020 |
Why?
|
Colectomy | 1 | 2013 | 697 | 0.020 |
Why?
|
Benzhydryl Compounds | 1 | 2014 | 939 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2013 | 2910 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2011 | 2229 | 0.020 |
Why?
|
Postoperative Care | 1 | 2013 | 1470 | 0.020 |
Why?
|
Central Nervous System Stimulants | 1 | 2014 | 1167 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2013 | 1509 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10729 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2019 | 3278 | 0.020 |
Why?
|
Anti-Infective Agents | 1 | 2013 | 986 | 0.020 |
Why?
|
Palliative Care | 1 | 2020 | 3645 | 0.020 |
Why?
|
Blood-Brain Barrier | 1 | 2011 | 1037 | 0.010 |
Why?
|
Physical Examination | 1 | 2010 | 1266 | 0.010 |
Why?
|
Glucose | 1 | 2016 | 4335 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5370 | 0.010 |
Why?
|
Remission Induction | 1 | 2009 | 2411 | 0.010 |
Why?
|
Counseling | 1 | 2010 | 1551 | 0.010 |
Why?
|
Educational Status | 1 | 2010 | 2513 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2015 | 3475 | 0.010 |
Why?
|
Databases, Factual | 1 | 2017 | 8067 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2021 | 16047 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2013 | 4348 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2016 | 14448 | 0.010 |
Why?
|
Mice | 2 | 2018 | 81819 | 0.010 |
Why?
|
Animals | 3 | 2018 | 168764 | 0.010 |
Why?
|
Thrombosis | 1 | 2013 | 2949 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12056 | 0.010 |
Why?
|
Neoadjuvant Therapy | 1 | 2009 | 2895 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2016 | 22332 | 0.010 |
Why?
|
Disease Progression | 1 | 2014 | 13632 | 0.010 |
Why?
|
Anticoagulants | 1 | 2013 | 4862 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2024 | 36532 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2012 | 3413 | 0.010 |
Why?
|
Massachusetts | 1 | 2008 | 8875 | 0.010 |
Why?
|
Logistic Models | 1 | 2008 | 13266 | 0.010 |
Why?
|
Models, Biological | 1 | 2009 | 9443 | 0.010 |
Why?
|
Signal Transduction | 1 | 2016 | 23601 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2013 | 26346 | 0.010 |
Why?
|
Mass Screening | 1 | 2008 | 5446 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2008 | 15398 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2013 | 15747 | 0.010 |
Why?
|